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MR-PheWAS: hypothesis 
prioritization among potential 
causal effects of body mass 
index on many outcomes, using 
Mendelian randomization
Louise A. C. Millard1,2, Neil M. Davies1, Nic J. Timpson1, Kate Tilling1, Peter A. Flach1,2 & 
George Davey Smith1
Observational cohort studies can provide rich datasets with a diverse range of phenotypic variables. 
However, hypothesis-driven epidemiological analyses by definition only test particular hypotheses 
chosen by researchers. Furthermore, observational analyses may not provide robust evidence of 
causality, as they are susceptible to confounding, reverse causation and measurement error. Using 
body mass index (BMI) as an exemplar, we demonstrate a novel extension to the phenome-wide 
association study (pheWAS) approach, using automated screening with genotypic instruments to 
screen for causal associations amongst any number of phenotypic outcomes. We used a sample 
of 8,121 children from the ALSPAC dataset, and tested the linear association of a BMI-associated 
allele score with 172 phenotypic outcomes (with variable sample sizes). We also performed an 
instrumental variable analysis to estimate the causal effect of BMI on each phenotype. We found 21 
of the 172 outcomes were associated with the allele score at an unadjusted p < 0.05 threshold, and 
use Bonferroni corrections, permutation testing and estimates of the false discovery rate to consider 
the strength of results given the number of tests performed. The most strongly associated outcomes 
included leptin, lipid profile, and blood pressure. We also found novel evidence of effects of BMI on a 
global self-worth score.
Epidemiology is typically hypothesis-driven, using prior knowledge to specify a hypothesis to be tested. 
However this can bias epidemiological research to hypotheses where there is a prior belief that an asso-
ciation exists. Also, the analyst’s research interests and preconceptions about the composition of causal 
pathways affects the hypotheses they decide to test. Candidate gene studies in genetic epidemiology pro-
vide an example of this, with hypothesis-driven approaches producing largely non-replicable findings1,2. 
An alternative approach is to use hypothesis-searching methods to identify associations to follow-up, 
where a set of hypotheses is systematically tested using a pre-specified test for association. For example, 
the hypothesis-searching genome-wide association study (GWAS) approach, with appropriate statistical 
testing, has generated highly replicable results3,4. There is little reason to presume that hypothesis-driven 
phenotypic studies will be substantially more successful than candidate gene studies, as their reporting 
in the literature is also likely to be biased due to small sample sizes and publication bias, in addition to 
the widely appreciated problems inherent in observational epidemiological research5.
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Epidemiologists have struggled to identify causal relationships using observational data because an 
observed association between an exposure and outcome may be due not only to chance but also to 
unknown/unmeasured confounders, residual confounding from measurement error in known confound-
ers, and reverse causation6,7. Mendelian randomization can help researchers infer causation by using 
instrumental variables (IVs) constructed from genetic variants8,9. This follows from the two (approxi-
mate) laws of Mendelian genetics: the Law of Segregation (Mendel’s first law) and the Law of Independent 
Assortment (Mendel’s second law). These laws imply that, linkage disequilibrium accepted, genetic vari-
ants are unlikely to be associated with confounding phenotypic or genetic factors10.
A robust approach to Mendelian randomization is to estimate the association of genetic variants 
directly with the outcome. This provides a valid test of whether an exposure causes an outcome and only 
depends on the three core instrumental variable assumptions11. These are: (1) the instrumental variable 
is associated with the exposure, (2) the instrumental variable is not associated with the factors that 
confound the association between the exposure and outcome, and (3) the instrumental variable is asso-
ciated with the outcome solely through the exposure12. Pleiotropy, linkage disequilibrium or population 
stratification can invalidate these assumptions. In order to estimate the size of the effect of an exposure 
on an outcome, the exposure phenotype must also be used in the analysis. When the exposure is used 
in the analysis the instrumental variable assumptions may be invalidated in other ways, such as if the 
instrument affects the outcome through the exposure phenotype at other time points than those included 
in the analysis. For instance, if body mass index (BMI) at age 2 and at age 25 both affected coronary heart 
disease, the published allele score for BMI could not identify the independent effects of BMI at these time 
points13. Furthermore, researchers must impose stronger, point identifying assumptions to estimate the 
size of the effect of the exposure on the outcome. For example, epidemiologists have commonly assumed 
constant treatment effects or no effect modification for continuous outcomes, or no effect modification 
for binary outcomes14. Researchers can investigate the validity of the core instrumental variable assump-
tions if multiple genetic variants are associated with the exposure. If two or more variants affect an 
exposure through different causal pathways, and the core instrumental variable assumptions and either 
of the point identifying assumptions hold, the variants should estimate the same size of causal effect of 
the exposure on the outcome12.
Hypothesis-searching is an established method to find genomic associations in GWAS, where little 
may be known about which genes influence an outcome. Recently, there have also been environment-wide 
association studies (EWAS)15,16 that search a large set of potential hypotheses (such as the association of 
blood pressure with a range of nutrients16). One study17 used previous GWAS and EWAS results (from15) 
to inform a hypothesis space to search for gene-environment interactions in order to minimize the num-
ber of tests carried out (which grows exponentially for interaction tests). The phenome-wide association 
study (pheWAS) approach has been used to investigate the association between a set of genetic variants 
and a set of phenotypes, testing the association of each genetic variant, phenotype pair individually18. The 
rapidly expanding number of genetic variants with known associations means the pheWAS approach can 
be extended to test for causal relationships using Mendelian randomisation15,19,20.
We aimed to illustrate how Mendelian randomization can be used to investigate the effects of an expo-
sure on a large set of outcomes, to identify outcomes potentially causally influenced by the exposure. We 
call this approach MR-pheWAS (Mendelian randomisation-pheWAS). As with GWAS, this is a screening 
approach where identified associations need to be validated through targeted replication studies. The 
aim of this work is to illustrate this hypothesis-searching method, and we use a set of positive controls 
to evaluate its effectiveness.
We will use the relationship between BMI, BMI genetic variants and a range of outcomes as an exem-
plar. BMI has a close relationship with many traits and is associated with diseases such as type 2 diabetes 
and cardiovascular disease21. An association between BMI and a phenotype may be due to confounding 
or because the phenotype affects BMI, rather than because BMI affects the phenotype. For instance, 
clinical trials have shown BMI is affected by environmental factors such as diet and exercise22,23. We 
build upon previous Mendelian randomization studies that have investigated the causal effects of BMI on 
inflammation, cancer, age at menarche, diabetes, atherosclerosis risk and blood pressure and hyperten-
sion21,24–33 and bi-directional studies that have analysed the effects of BMI and a second exposure such 
as C-reactive protein28,34, serum uric acid35,36, vitamin-D37 and fetuin-A38.
Results
The association between the BMI allele score and observed BMI across childhood strengthens with age 
and stabilizes at around age 10 (Table 1). A standard deviation increase in BMI allele score was associated 
with a 0.163 standard deviation increase in log BMI at age 8 (95% confidence interval (CI): 0.14, 0.19, 
F = 140.66). Furthermore, we found little evidence of associations with common socio-economic con-
founders compared with many strong associations for observational BMI at age 8 (Table 2). These tests 
support the notion that the BMI allele score may be a valid instrument for life-long BMI.
Our stage 1 tests found the BMI allele score was associated with 21 outcomes, using an unadjusted 
P < 0.05 threshold (Table 3). Of these, 14 outcomes were from the 160 outcomes we randomly included 
in our dataset (test of proportions P = 0.030), compared to 8 expected by chance alone (160 × 0.05, 
making the conservative assumption that all outcomes are uncorrelated). Hence we would expect 6 of 
the 14 identified outcomes to be true associations (false discovery rate of 0.571). We found stronger 
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associations than would be expected by chance, illustrated by the QQ plot in Fig. 1, suggesting that BMI 
affects many outcomes. After Bonferroni correction only HDL at age 9 was found with a P value below 
P < 0.05 whereas using the permutation P values we found 8 associations with P <0.05. In comparison, 
we found 57 stage 1 associations with P < 0.05 using observational BMI at age 8. Of these, 48 were from 
the 160 randomly included in our dataset (test of proportions P = < 0.001), compared to 8 expected by 
chance alone. The instrumental variable effect estimates (stage 2 results) are given in Table 4 and Figs 2 
and 3 (and observational estimates are also provided for comparison).
The stage 1 direct tests identified several known associations, such as with leptin and age at menarche. 
The two-stage least squares IV analysis estimated that a 1 SD increase in log BMI at age 8 increased log 
leptin at age 9 by 0.92 SD (95% confidence interval (CI): 0.77, 1.07), which equates to a 0.05% increase in 
leptin per 1% increase in BMI age 8. A 1 SD increase in log BMI at age 8 was associated with a 201.7 day 
earlier age at menarche (95% CI: 112.3, 291.1), which equates to a 15.5 day earlier age at menarche (95% 
CI: 8.53, 22.57) for a 1% increase in BMI age 8. We also identified novel effects of BMI. For instance, a 
1 SD increase in log BMI at age 8 increased the odds of having a global self-worth score ≥ 20 by 53.7% 
(95% CI: 10.2, 214.2), which equates to a 37.1% (95% CI: 7.4, 75.1) increase in the odds of having a 
global self-worth score ≥ 20, for a 10% increase in BMI age 8. We list all outcomes in our dataset in 
Supplementary Table 3 and the results of the stage 1 tests in Supplementary Table 4, so that readers can 
view results where the CI includes the null value. The observational estimates were nearer the null than 
the IV estimates, and we found differences between the IV and observational estimates for 6 phenotypes, 
using the Durbin-Wu-Hausman test (Table 4).
Evidence of violation of IV assumptions. The 31 SNP score and FTO allele were both strong 
instruments for log BMI at age 8. A 1 SD increase of the 31-SNP score was associated with a 0.146 
standard deviation increase in log BMI at age 8 (95% CI: 0.12, 0.17, F = 112.70). A 1 SD increase of 
FTO was associated with a 0.074 standard deviation increase in log BMI at age 8 (95% CI: 0.05, 0.10, 
F = 28.18). We found little evidence of pleiotropy, linkage disequilibrium or population stratification as 
the tests with the FTO and 31-SNP scores were highly consistent (Figs 4 and 5 and Table 5). We found 
evidence using the Hansen tests of differences between the estimated effects of BMI using each instru-
ment for 5 outcomes: apolipoprotein AI, apolipoprotein B, insulin, leptin and the emotional symptoms 
score (Table 6). This may be due to chance, or alternatively may suggest that the genetic variants related 
to BMI have pleiotropic or heterogeneous effects on these outcomes.
Table 1 shows the associations of FTO and the 31-allele score respectively, with BMI across childhood. 
We found evidence of an inverse association of FTO with BMI in early childhood, as previously sug-
gested39. For instance, an increase of 1 BMI increasing FTO allele was associated with a 0.059 decrease of 
log BMI at age 1 year 8 months (95% CI: − 0.096, − 0.022). In contrast, the 31-allele score was positively 
associated with BMI at all ages measured.
Number with 
measured 
BMI
Mean age at BMI 
measurement
SD increase of log BMI during childhood 
per 1 SD increase of BMI allele score 
with 32 SNP variants
SD increase of log BMI during childhood 
per 1 SD increase of FTO allele dosages
SD increase of log BMI during 
childhood per 1 SD increase of BMI 
allele score with 31 SNP variants  
(FTO removed)
SD 
change 95% CI F-statistica
SD 
change 95% CI F-statistica
SD 
change 95% CI F-statistica
6,601 7.48 wks 0.016 − 0.01, 0.04 1.65 − 0.018 − 0.04, 0.01 2.12 0.025 0.00, 0.05 4.22
6,282 40.50 wks 0.032 0.01, 0.06 6.36 − 0.029 − 0.05, 0.00 5.19 0.047 0.02, 0.07 14.10
5,797 1.69 yrs 0.036 0.01, 0.06 7.42 − 0.041 − 0.07, − 0.02 9.66 0.056 0.03, 0.08 18.78
5,430 3.71 yrs 0.068 0.04, 0.09 25.29 − 0.004 − 0.03, 0.02 0.10 0.075 0.05, 0.10 31.39
6,076 7.57 yrs 0.142 0.12, 0.17 125.00 0.049 0.02, 0.07 14.88 0.133 0.11, 0.16 109.75
5,087 8.68 yrs 0.163 0.14, 0.19 140.66 0.074 0.05, 0.10 28.18 0.146 0.12, 0.17 112.70
5,623 10.68 yrs 0.175 0.15, 0.20 175.27 0.090 0.06, 0.12 45.96 0.150 0.12, 0.18 128.80
5,116 12.80 yrs 0.170 0.14, 0.20 151.21 0.082 0.05, 0.11 35.28 0.150 0.12, 0.18 116.58
4,746 13.83 yrs 0.167 0.14, 0.19 134.07 0.074 0.05, 0.10 26.78 0.150 0.12, 0.18 107.05
4,174 15.45 yrs 0.158 0.13, 0.19 106.35 0.071 0.04, 0.10 21.60 0.142 0.11, 0.17 84.49
2,665 17.04 yrs 0.176 0.14, 0.21 83.94 0.086 0.05, 0.12 20.14 0.153 0.12, 0.19 63.13
Table 1.  Associations of BMI allele score with BMI across childhood. Abbreviations: BMI, body mass 
index; CI, confidence interval; SD, standard deviation; wks, weeks; yrs, years. All BMI variables are log 
transformed. BMI calculated as weight (kilograms) divided by height (metres squared). Based on the original 
data of 8,121 participants (variable sample size per BMI measurement). aF-statistic: Measure of strength of 
association between exposure and outcome.
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Sensitivity analyses. As shown in Fig.  6, the outcomes had varying numbers of missing values, 
which means there were differences in statistical power across outcomes. However, the ranking of our 
main analysis is highly correlated with the ranking of the imputation dataset (Spearman’s rank correla-
tion of 0.919 (P < 0.001)). Results using the imputed dataset are given in Supplementary Table 4.
We looked for further evidence of the associations identified during our main analyses by repeating 
the two-stage least squares IV analysis of the second stage using a 52-SNP BMI allele score instead of the 
32-SNP score. A standard deviation increase in the 52-SNP BMI allele score was associated with a 0.080 
standard deviation increase in log BMI at age 8 (95% confidence interval (CI): 0.05, 0.11, F = 33.21). 
The two-stage least squares IV analysis estimates using the 52-SNP BMI allele score were consistent with 
those using the 32-SNP score (see Supplementary Figures 1 and 2).
Discussion
Epidemiologists have struggled to produce robust replicable evidence of the causal effect of risk fac-
tors40. Population geneticists have been extremely successful in using hypothesis-searching approaches to 
produce replicable associations. We have shown that it is possible to use a similar hypothesis-searching 
approach, using Mendelian randomization to highlight the strongest effects of an exposure in a large 
sample of individuals.
We used a Mendelian randomization analysis to screen for potentially causal effects. Our stage 1 
analysis tested the association of the BMI allele score directly with each of the outcomes. Identifying 
known effects with this approach validates the use of this score as an instrument for life-long BMI. The 
Potential confounder
Sample 
size
SD change of BMI allele score for a 
1 SD change of confounder
Sample 
size
SD change of log BMI age 8 for a 1 SD 
change of confounder
SD 
change 95% CI P valued
SD 
change 95% CI P valued
Maternal educationa
 Less than O-level
7,306
Reference
0.871 4,735
Reference
0.001
 O-level − 0.02 − 0.08, 0.04 − 0.05 − 0.13, 0.03
 A-level 0.03 − 0.04, 0.09 − 0.05 − 0.13, 0.03
 Degree or above − 0.03 − 0.11, 0.04 − 0.16 − 0.25, − 0.07
Sex
 Female
8,121
Reference
5,087
Reference
 Male 0.00 − 0.05, 0.04 0.828 0.13 0.07, 0.18 < 0.001
Household social classb
 Class I (professional)
6,929
Reference
0.776 4,554
Reference
0.213
 Class II 0.01 − 0.06, 0.08 0.10 0.02, 0.18
 Class III (non-manual) − 0.01 − 0.08, 0.07 0.09 0.00, 0.19
 Class III (manual) − 0.01 − 0.11, 0.08 0.10 − 0.02, 0.21
 Class IV/V (manual) 0.02 − 0.11, 0.14 0.07 − 0.09, 0.23
Parityc
 0
7,408
Reference
0.850 4,741
Reference
0.789 1 − 0.03 − 0.08, 0.02 − 0.03 − 0.10, 0.03
 2 0.01 − 0.05, 0.07 0.01 − 0.07, 0.08
Mother smoking in pregnancy
 No
7,484
Reference
4,788
Reference
 Yes 0.02 − 0.03, 0.08 0.444 0.18 0.11, 0.25 <0.001
Table 2.  Association of BMI allele score and observational BMI at age 8 with potential confounders 
of BMI. Abbreviations: SD, standard deviation; CI, confidence interval; BMI, body mass index. aMaternal 
education: O-level (ordinary level) exams are taken in different subjects usually at age 15–16 at the 
completion of legally required school attendance, equivalent to today’s General Certificate of Secondary 
Education); A-level (Advanced-level) exams are taken in different subjects usually at age 18). bHousehold 
social class: The mother recorded the occupation of both herself and her partner in a questionnaire at 32 
weeks gestation, which were used to allocate them to social class groups using the 1991 Office of Population, 
Censuses and Surveys classification; the highest class of the mother and her partner was used in analysis. 
cParity: Obtained from obstetric records. Mothers with parity of two or more were grouped into a single 
category. dP values for linear trend given if more than two ordinal categories.
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BMI allele score was most strongly associated with leptin, which is produced in adipose tissue and is 
involved in satiation41. This result is consistent with previous research28. Also consistent with previous 
studies, we identified effects of BMI on the following metabolic traits: glucose, insulin, interleukin-6, 
systolic blood pressure24, low and high density lipoprotein cholesterol, triglycerides, and C-reactive 
protein21,27,28,31,34,42,43. The BMI allele score was also strongly inversely associated with age at menarche. 
Previous observational studies have reported that age at menarche is inversely associated with BMI44, and 
a recent study also used Mendelian randomization to argue that BMI affects age at menarche25. We found 
a novel positive effect of BMI on a global self-worth score. We did not replicate the novel associations, as 
our aim in this work is to carry out a proof-of-principle analysis demonstrating our hypothesis-searching 
method. We found more associations using BMI aged 8 than with the BMI allele score. This may be due 
to reverse causation (because some of the “outcomes” actually affect BMI) or due to confounding, and 
Rank
Outcome variable  
(original data with variable N)
SD change of inverse normal transformed outcome for a 1 SD change of 
BMI allele score
Sample 
size
SD 
change 95% CI
P value  
(adjusted P value)a
Permutation 
P valueb
1 Leptin, 9c 4,249 0.138 0.11, 0.17 < 0.001 –
2 CRP, 9c 4,250 0.083 0.05, 0.11 < 0.001 –
3 Age menarchec 2,946 − 0.083 − 0.12, − 0.05 < 0.001 –
4 HDL, 9 4,250 − 0.067 − 0.10, − 0.04 < 0.001 (0.002) 0.008
5 SBP, 7c 6,013 0.049 0.02, 0.07 < 0.001 –
6 IL6, 9 4,240 0.053 0.02, 0.08 0.001, (0.091) 0.010
7 Enjoyment of School Score, 4 5,807 0.041 0.02, 0.07 0.002, (0.255) 0.022
8 Self Esteem: Scholastic Competence, 8 5,222 0.042 0.02, 0.07 0.002, (0.323) 0.025
9 Apolipoprotein B, 9 4,250 0.043 0.01, 0.07 0.005, (0.788) 0.028
10 Triglycerides, 9 4,250 0.042 0.01, 0.07 0.006, (0.970) 0.037
11 VLDL, 9 4,250 0.042 0.01, 0.07 0.006, (1) 0.048
12 Apolipoprotein al, 9 4,250 − 0.038 − 0.07, − 0.01 0.012, (1) 0.046
13 Insulin, 15c 2,859 0.047 0.01, 0.08 0.012 –
14 Attention/activity symptoms score, 11 4,541 0.037 0.01, 0.07 0.013, (1) 0.055
15 SDQ emotional symptoms score, 6 5,748 − 0.030 − 0.06, 0.00 0.022, (1) 0.063
16 Hygiene Score, 4 6,231 0.028 0.00, 0.05 0.024, (1) 0.070
17 Self Esteem: Global Self Worth Score, 8 5,214 0.031 0.00, 0.06 0.025, (1) 0.079
18 FVC: lung function, 8c 5,276 0.030 0.00, 0.06 0.030 − 
19 Burden of compulsions/obsessions score, 7 5,684 0.028 0.00, 0.05 0.031, (1) 0.080
20 Particular fears score, 7 5,734 − 0.028 − 0.05, 0.00 0.033, (1) 0.086
21 Glucose, 15c 2,862 0.041 0.11, 0.17 0.038 –
Table 3.  Ranking by association strength (P value) of the stage 1 tests with p < 0.05: Outcome 
associations with BMI allele score for original dataset. Abbreviations: BMI, body mass index; CI, 
confidence interval; SD, standard deviation; VLDL, very low density lipoprotein; IL6, interleukin 6; SBP, 
systolic blood pressure; HDL, high density lipoprotein; VLDL, very low density lipoprotein; SDQ, Strengths 
and Difficulties Questionnaires; LF, lung function; FVC, forced vital capacity. Full names of variables are 
given in Supplementary Table 3. All outcomes are transformed to normal distributions using a rank-
based inverse normal transformation. Exposure and outcome variables are standardised. Outcome as 
dependent variable, BMI allele score as independent variable. aAdjusted P values are adjusted for the 160 
tests performed using the Bonferroni correction: pcorrected = poriginal·160. Adjusted P values greater than 1 are 
rounded to 1. Outcomes in validation set are excluded from Bonferroni correction. bPermutation P values 
are generated with permutation testing. Null hypothesis: The outcome variable at rank i in this table would 
be ranked lower than i if no association was found with the allelic score. We exclude outcomes in validation 
set such that such that, for instance i = 1 for HDL because all three outcomes ranked higher than HDL are 
in the validation set). cVariables that are in the ‘validation set’, that were chosen for inclusion using apriori 
knowledge of their association with BMI. Adjusted P value are not given for these are they are not part of 
the main outcome dataset.
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this highlights the benefit of a Mendelian randomization analysis6. While this could be due to the lower 
power of tests with the allele score compared to observational BMI, when the stage 1 tests were repeated 
using an allele score composed of all 84 variants (combining the 52 and 32 SNP score) the number of 
results with p < 0.05 was comparable to that found using the 32 SNP score, (19 versus 21 respectively, 
test of proportions p = 0.737).
The observational estimates were consistently closer to the null than the IV estimates. This may be due 
to the winner’s curse because in the stage 1 we rank all 172 estimates of the allele score on the outcomes, 
such that the highest ranked are more likely to be higher than their respective true values because of the 
random variation of these sample estimates about their true values. The stage 2 estimates (also ranked by 
the stage 1 estimates) may also be affected by this winners curse because the stage 1 (direct) and stage 2 
models are highly related. The estimates using the observational BMI exposure may not affected to the 
same extent as they are ranked by the results using the BMI allele score, with which it is not perfectly 
correlated. Alternatively, the IV estimates may be more extreme than the observational estimates because 
the allelic score is a measure for life-long BMI, so the effect on outcomes may be larger due to the cumu-
lative effects of BMI across the life course.
The validity of our results depends on whether the instrumental variable assumptions hold, such that 
the genetic variants only affect the outcomes through BMI (the exposure). We ensured our BMI allele 
score was a strong instrument for BMI, and was not associated with common confounding variables such 
as sex and potential socio-economic confounders such as household social class. In contrast, BMI at age 8 
was associated with confounders consistent with the social patterning reported previously45-47. The allele 
score was composed of 32 BMI-associated genetic variants. While a larger number of SNPs increases the 
power to detect associations, this also means that the third instrumental variable assumption may be 
more likely to be invalid for at least one genetic variant included in the allele score.
A number of mechanisms could invalidate the third instrumental variable assumption: that the genetic 
variants only affect the outcomes through BMI at age 8. These include genetic induced confounding 
through horizontal pleiotropy (where a locus affects several outcomes directly9), population stratification 
and linkage disequilibrium, each of which could add a causal path from the IV to an outcome which 
was not mediated via BMI. The effect estimates when using two independent instruments (FTO and the 
remaining 31 variants) were consistent providing evidence against pleiotropy because it is unlikely that 
two independent instruments suffer the same pleiotropic effects. Furthermore, the IV estimates using 
the 52-SNP allele score were consistent with the IV estimates of our 32-SNP score. However, we found 
evidence of heterogeneity when testing the 32 SNPs individually using Hansen tests, for 5 of the 21 ‘top’ 
results. This may indicate either the core or point identifying IV assumptions are invalid. Any biases 
introduced by violations of these assumptions may be amplified due to the low power of the individual 
SNPs. This is because these weak instruments account for only a small proportion of the variance of 
BMI, such that their effect through BMI is small compared with the strength of the association through 
one of these alternative pathways13. Further tests to investigate heterogeneity could be performed in 
follow up analyses. For instance, plotting the effect of each SNP on BMI against the effect of each SNP 
on a particular outcome may identify SNPs causing the heterogeneity, where they deviate from this lin-
ear association that should pass through the plot origin48. Repeating the Hansen tests with these SNPs 
removed can demonstrate if they are driving the reported heterogeneity.
Figure 1. QQ-plot of the associations between the BMI allelic score and the 172 outcomes. Association 
of log BMI age 8 with outcomes, of the stage 1 tests. Using the original dataset with variable number of 
individuals for each outcome. Tests performed with the Stata regress command and robust option. 
Top result leptin is not shown as P value too small. Corrected P = 0.00023 line: The Bonferroni corrected 
P = 0.05, accounting for the 160 tests (excluding validation set) performed. P expected = actual line: The 
expected trajectory, assuming the P values are uniformly distributed.
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Rank
Outcome variable 
(original data with 
variable N)
Sample 
size
IV estimate of SD change of outcome for a 1 SD 
change of log BMI age 8a
SD change of outcome for a 1 SD change of log BMI 
(observational, age 8)
P valuee
Test 
statistic 95% CI
P value  
(adjusted P valueb)
Test 
statistic 95% CI
P value  
(adjusted P valueb)
Linear regression of continuous, normally distributed outcomes. Test statistic is the mean difference (SD) per 1 SD greater log BMI age 8 or percentage difference per 
1 SD greater log BMI age 8 for log transformed outcomesc
 1 Leptin, 9f 3,381 0.922 0.77, 1.07 < 0.001 0.688 0.66, 0.71 < 0.001 0.002
 2 CRP, 9f 3,382 0.432 0.25, 0.62 < 0.001 0.367 0.33, 0.40 < 0.001 0.484
 3 Age menarchef 2,186 − 0.485 − 0.70, − 0.27 < 0.001 − 0.298 − 0.34, − 0.26 < 0.001 0.080
 4 HDL, 9 3,382 − 0.466 − 0.66, − 0.27 < 0.001 (< 0.001) − 0.303 − 0.34, − 0.27 < 0.001 (< 0.001) 0.096
 5 SBP, 7f 4,641 0.305 0.13, 0.48 0.001 0.312 0.28, 0.34 < 0.001 0.940
 6 IL6, 9 3,372 0.234 0.04, 0.43 0.018 (2.852) 0.197 0.17, 0.23 < 0.001 (< 0.001) 0.709
 9 Apolipoprotein B, 9 3,382 0.363 0.16, 0.57 < 0.001 (0.080) 0.163 0.13, 0.20 < 0.001 (< 0.001) 0.048
 10 Triglycerides, 9 3,382 0.310 0.11, 0.51 0.002 (0.341) 0.226 0.19, 0.26 < 0.001 (< 0.001) 0.392
 11 VLDL age 9 3,382 0.310 0.11, 0.51 0.002 (0.343) 0.226 0.19, 0.26 < 0.001 (< 0.001) 0.393
 12 Apolipoprotein al, 9 3,382 − 0.243 − 0.44, − 0.05 0.016 (1) − 0.196 − 0.23, − 0.16 < 0.001 (< 0.001) 0.636
 13 Insulin, 15f 2,285 0.299 0.06, 0.53 0.013 0.202 0.16, 0.24 < 0.001 0.434
 16 Hygiene Score, 4 4,335 0.209 0.01, 0.41 0.042 (1) 0.052 0.02, 0.08 0.001 (0.086) 0.118
 18 FVC: lung function, 8f 4,869 0.162 0.00, 0.32 0.052 0.147 0.12, 0.18 < 0.001 0.855
 21 Glucose, 15f 2,288 0.334 0.02, 0.65 0.039 0.006 − 0.04, 0.05 0.819 0.012
Logistic regression of binary outcomes. Test statistic is the odds ratio between outcome groupsd for a 1 SD increase in log BMI age 8
 7 Enjoyment of School Score, 4 5,808 1.344 0.98, 1.84 0.066 (1) 1.075 1.01, 1.14 0.025 (1) 0.700
 8 Self Esteem: Scholastic Competence, 8 5,223 1.548 1.11, 2.16 0.010 (1) 1.004 0.95, 1.06 0.896 (1) 0.036
 14 Attention/activity symptoms score, 11 4,542 1.399 0.96, 2.03 0.079 (1) 1.022 0.95, 1.10 0.570 (1) 0.166
 15 SDQ emotional symptoms score, 6 5,749 0.856 0.62, 1.19 0.357 (1) 0.947 0.88, 1.01 0.095 (1) 0.543
 17 Self Esteem: Global Self Worth Score, 8 5,215 1.536 1.10, 2.14 0.011 (1) 1.002 0.95, 1.06 0.932 (1) 0.046
 19 Burden of compulsions/obsessions score, 7 5,685 2.258 0.74, 6.92 0.154 (1) 0.970 0.67, 1.27 0.842 (1) 0.507
 20 Particular fears score, 7 5,735 0.893 0.65, 1.23 0.487 (1) 0.992 0.93, 1.05 0.792 (1) 0.519
Table 4.  Ranked outcome associations with BMI allele score for original dataset, for results with 
P < 0.05. Abbreviations: BMI, body mass index; CI, confidence interval; SD, standard deviation; IV, 
instrumental variable; VLDL, very low density lipoprotein; IL6, interleukin 6; SBP, systolic blood pressure; 
HDL, high density lipoprotein; SDQ, Strengths and Difficulties Questionnaires; FEF, forced expiratory 
flow; LF, lung function; FVC, forced vital capacity. Full names of variables are given in Supplementary 
Table 3. Figures 2 and 3 shows these results graphically. The ranks are based on tests of association of the 
BMI allele score with the outcome directly, for the 22 associations with a p < 0.05. We then perform IV 
analysis of these results, and it is the IV estimate that is given in this table. Exposure and outcome variables 
are standardized. Outcome as dependent variable, BMI allele score as independent variable. aContinuous 
outcomes: Using Stata ivreg2 command (robust option) and BMI allele score as instrumental variable 
for log BMI age 8. First stage predicting log BMI at age 8 with the BMI allele score, and the second 
stage performs an unadjusted association of these log BMI age 8 predictions with the outcome. Binary 
outcomes: Using regress command (robust option) for first stage, and logistic command (vce(robust) 
option) for the second stage, to associate outcome with the predicted values of log BMI age 8 from the 
first stage. bAdjusted P values: Adjusted for the 160 tests performed using the Bonferroni correction: 
pcorrected = poriginal·160. Adjusted P values greater than 1 are rounded to 1. Outcomes in validation set are 
excluded from Bonferroni correction. cLog transformed outcomes, such that distributions approximately 
normal. dCategories for binary variables given in Supplementary Table 7. eP value of Durbin-Wu-Hausman 
test, comparing the effect estimates using the allelic score with the effect estimates using observational log 
BMI age 8. This uses a test for endogeneity (endog argument of ivreg2 Stata command). fVariables that 
are in the ‘validation set’, that were chosen for inclusion using a priori knowledge of their association with 
BMI.
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The stage 1 analysis estimated the association of the BMI allelic score and each outcome, rather than 
providing an estimate of the effect size, as is estimated in the stage 2 IV analysis. While an estimate of 
the effect size is generally preferable, the stage 1 tests are important to consider because they only depend 
on the core IV assumptions, whereas the stage 2 tests also require point identifying assumptions. Also, 
some of the ways the IV assumptions can become invalidated are circumvented in the stage 1 tests. This 
is because the stage 1 test requires the exposure to be defined, but a variable representing this exposure 
is not actually used in the test of association. This is useful because the BMI allelic score is a measure 
of lifelong risk of increased BMI, but we only have measures of observational BMI at a set of discrete 
time points, rather than a composite measure representing observational lifelong BMI. The use of BMI 
at a single time point, at age 8, is a valid exposure if all pathways through BMI at all other ages (prior to 
measurement of the outcome) also pass through BMI at age 8. If this is not the case (and this is likely) 
then the IV assumptions are false. For example, we found a different effect of the FTO SNP and 31 SNP 
allele score on BMI in early childhood, which indicates that these variants affect BMI through different 
pathways. Any pathway from the genetic variants to an outcome through BMI at an age other than age 8 
would invalidate the instrumental variable assumptions. This is not a problem for our stage 1 tests, as we 
need only specify the exposure as ‘lifelong BMI up to the point of outcome measurement’. Furthermore, 
this removes the issue of measurement error in the observed exposure variable since it is not actually 
used in the model.
Figure 2. A comparison of the observational and instrumental variable estimates for continuous 
outcomes. The standard deviation change of outcome for a 1 SD increase of log BMI aged 8. IV estimate 
of effect using two-stage least squares regression of log BMI at age 8 as the exposure, with robust option. 
Observational estimates are the SD change of the outcome for a 1 SD increase in log BMI at age 8. Graphical 
illustration of the results in Table 4.
Figure 3. A comparison of the observational and instrumental variable estimates for binary outcomes. 
Odds ratio between groups of outcomes, for a 1 SD change of log BMI aged 8. IV estimate of effect using 
two-stage least squares regression of log BMI at age 8 as the exposure, with robust option. Observational 
estimates are the odds ratio between outcome groups. Graphical illustration of the results in Table 4. 
Categories for binary variables given in Supplementary Table 7.
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We now discuss some further limitations of our analysis. We tested only for linear relationships and 
hence it is possible that non-linear relationships exist. We used an inverse rank normal transformation, 
which may not be appropriate for numeric outcomes with only a small number of values, as the rank 
within each set with the same value is randomly generated, and this may add noise to the data. Ranking 
results means that we should expect the true strength of associations to be less than we reported, due to 
the winner’s curse. This means that the effect sizes are not reliable and need replicating in a hypothesis 
driven manner. However, conventional epidemiological studies also suffer this due to flexibility in study 
design, where several methods may be used in turn to examine a particular relationship and the strong-
est result reported49. The size of an effect estimate may be reduced due to developmental compensation 
(or canalisation) where a foetus may develop to protect itself from the adverse effects of a particular 
polymorphism that is expressed during foetal development. This protection may continue throughout 
the life course such that a high BMI will have fewer health implications, and our reported associations 
may be reduced8,9. Dynastic effects, where the outcome trait of the child is also affected by the parental 
exposure caused by the parental genotype, can also affect the size of an effect estimate. The effect may be 
exaggerated because the child has greater exposure, or reduced if the parent’s genotype creates an adverse 
environment during pregnancy from which the foetus then develops to protect against.
Our dataset included the most complete version of each repeated measure, which was usually at the 
earlier time point. While this may improve the statistical power of our tests, this benefit may be offset 
by the reduction of power because associations are often less pronounced at younger ages (as shown in 
Figure 4. Testing invalidity of IV assumptions: associations of two instrumental variables using distinct 
SNP subsets, for continuous outcomes. Comparison between the SNP subsets: (1) 31 SNPs (excluding FTO 
SNP) and (2) the FTO SNP only. IV estimate of effect using two-stage least squared regression of log BMI at 
age 8 as the exposure. Graphical illustration of the results in Table 5.
Figure 5. Testing invalidity of IV assumptions: associations of two instrumental variables using distinct 
SNP subsets, of binary outcomes. Odds ratio between outcome groups, for a 1 SD change of log BMI aged 
8. Comparison between the SNP subsets: (1) 31 SNPs (excluding FTO SNP) and (2) the FTO SNP only. IV 
estimate of effect using two-stage least squared regression of log BMI at age 8 as the exposure. Graphical 
illustration of the results in Table 5. Categories for binary variables are given in Supplementary Table 7.
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Table  1 for BMI). Mendelian randomization analyses have low statistical power compared to conven-
tional observational analyses, because genetic variants typically only explain a small proportion of an 
exposure’s variance. Although we used a combined allelic score to maximize the power from the genetic 
predictors, some associations may not have been detected due to a lack of power. Furthermore, perform-
ing multiple tests reduces the statistical power as we need to account for the number of independent tests 
we performed. The varying degrees of missingness of the outcome variables means: (1) it is possible the 
associations are biased if the outcome data are not missing at random (conditional on the variables in 
the model, i.e. observed BMI or the allelic score), and (2) the ranking may be affected by differences in 
power amongst the outcomes, including false negative results where the power is too low to detect an 
association. Using the time point with the largest available sample sizes for each trait reduces the risk of 
bias due to missingness.
Outcome variable  
(original data with variable N)
IV estimate using 31 SNPs excluding 
FTO SNPa IV estimate using FTO SNPa only
Hansen P 
valuee
Test 
statistic 95% CI P valuec
Test 
statistic 95% CI P valuec
Linear regression of continuous normally distributed outcomes. Test statistic is the mean difference (SD) per 1 SD greater log BMI age 8 
or percentage difference per 1 SD greater log BMI age 8d
 Leptin, 9b,d 0.851 0.68, 1.02 < 0.001 1.193 0.85, 1.54 < 0.001 0.051
 CRP, 9b,d 0.447 0.24, 0.66 < 0.001 0.375 0.01, 0.74 0.042 0.735
 Age menarcheb − 0.443 − 0.70, − 0.19 0.001 − 0.631 − 1.05, − 0.21 0.003 0.449
 HDL, 9d − 0.517 − 0.75, − 0.29 < 0.001 − 0.271 − 0.64, 0.10 0.153 0.275
 SBP, 7b 0.290 0.10, 0.48 0.002 0.385 − 0.05, 0.83 0.086 0.694
 IL6, 9d 0.300 0.08, 0.52 0.008 − 0.027 − 0.41, 0.36 0.891 0.136
 Apolipoprotein B, 9 0.281 0.05, 0.51 0.018 0.678 0.24, 1.12 0.003 0.098
 Triglycerides, 9d 0.262 0.04, 0.49 0.023 0.496 0.09, 0.90 0.016 0.307
 VLDL age 9d 0.261 0.04, 0.49 0.023 0.497 0.09, 0.90 0.016 0.303
 Apolipoprotein al, 9 − 0.275 − 0.51, − 0.04 0.021 − 0.122 − 0.50, 0.26 0.533 0.509
 Insulin, 15b,d 0.214 − 0.05, 0.48 0.116 0.634 0.08, 1.19 0.026 0.163
 Hygiene Score, 4 0.241 0.02, 0.46 0.032 0.045 − 0.44, 0.53 0.858 0.477
 FVC: lung function, 8b 0.226 0.04, 0.41 0.016 − 0.116 − 0.49, 0.25 0.540 0.096
 Glucose, 15b 0.423 0.06, 0.78 0.021 − 0.018 − 0.56, 0.52 0.949 0.161
Logistic regression of binary outcomes. Test statistic is the odds ratio between groups for a 1 SD increase in log BMI age 8
 Enjoyment of School 
Score, 4 1.349 0.95, 1.92 0.096 1.319 0.66, 2.64 0.435 0.897
 Self Esteem: Scholastic 
Competence, 8 1.665 1.15, 2.41 0.007 1.122 0.54, 2.34 0.759 0.517
 Attention/activity 
symptoms score, 11 1.534 1.01, 2.32 0.043 0.916 0.40, 2.07 0.832 0.882
 SDQ emotional symptoms 
score, 6 0.816 0.56, 1.18 0.277 1.072 0.52, 2.22 0.852 0.815
 Self  Esteem: Global Self 
Worth Score, 8 1.723 1.19, 2.50 0.004 0.926 0.45, 1.93 0.837 0.357
 Burden of compulsions/
obsessions score, 7 2.241 0.60, 8.44 0.233 2.255 0.14, 36.76 0.568 0.734
 Particular fears score, 7 0.864 0.61, 1.23 0.418 1.041 0.52, 2.10 0.910 0.901
Table 5.  Testing for invalidity of IV assumptions: associations of two instrumental variables for log BMI 
at age 8; using 31 SNPs (excluding FTO SNP) and only the FTO SNP respectively. Abbreviations: BMI, 
body mass index; CI, confidence interval; SD, standard deviation; IV, instrumental variable; VLDL, very low 
density lipoprotein; IL6, interleukin 6; SBP, systolic blood pressure; HDL, high density lipoprotein; SDQ, 
Strengths and Difficulties Questionnaires; LF, lung function; FVC, forced vital capacity. IV estimate calculated 
with ivregress and robust option (for robust standard errors). Categories for binary variables are given 
in Supplementary Table 7. Full names of variables are given in Supplementary Table 3. Figures 4 and  5 show 
these results graphically. aFTO SNP is rs1558902. bVariables that are in the ‘validation set’, that were chosen 
for inclusion using a priori knowledge of their association with BMI. cP values are not adjusted for the 
multiple tests performed. dLog transformed outcomes, such that distributions approximately normal. eHansen 
P value comparing effect estimates using 31 SNP score and FTO.
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Traditionally, hypothesis-driven studies, where many hypotheses are tested independently by several 
research teams, suffer the issues of multiple testing and selection bias from the researcher choosing which 
hypothesis to test and the methods to use, as well as publication bias50. A large proportion of null findings 
are unpublished such that it is not possible to determine the true probability the reported result would 
occur by chance. This is a most problematic form of multiple testing because we cannot know how many 
and what associations have be tested. In contrast, by searching for hypotheses in a single study we are 
able to report the results of all analyses, including ‘null’ results, so that our work does not contribute to 
this publication bias. We have provided the results of all stage 1 tests in the Supplementary Material. We 
presented unadjusted and Bonferroni corrected P values, and estimated a false discovery rate of 0.571, 
such that 6 of the 14 associations we found with a P value < 0.05 (excluding our validation set) may 
indicate causal relationships between BMI and these outcomes. Given the high degree of confounding in 
observational data, the adjusted P values and false discovery rate are likely to be conservative estimates, 
because they both account for the number of independent tests, but the outcomes in our dataset are not 
independent. We also provide permutation testing P values that are an appropriate way to assess the 
results as this method implicitly accounts for the number of tests performed. A result is less likely to 
achieve a rank of 1 by chance alone as the number of tests increases. The P values of the Bonferroni and 
Outcome variable (original data 
with variable N)
CUEa
Test statistic 95% CI P valueb
Hansen P 
valueb
Linear regression of continuous normally distributed outcomes. Test statistic is the mean difference 
(SD) per 1 SD greater log BMI age 8 or percentage difference per 1 SD greater log BMI age 8d
 Leptin, 9c 0.934 0.74, 1.13  < 0.001 0.019
 CRP, 9c 0.410 0.22, 0.60  < 0.001 0.606
 Age menarche − 0.508 − 0.82, − 0.20 0.001 0.077
 HDL, 9c − 0.447 − 0.65, − 0.24  < 0.001 0.388
 SBP, 7 0.314 0.12, 0.50 0.001 0.456
 IL6, 9c 0.250 0.07, 0.43 0.006 0.885
 Apolipoprotein B, 9 0.339 0.04, 0.64 0.028 0.010
 Triglycerides, 9c 0.245 0.04, 0.45 0.020 0.455
 VLDL age 9c 0.245 0.04, 0.45 0.020 0.454
 Apolipoprotein al, 9 − 0.302 − 0.53, − 0.07 0.010 0.005
 Insulin, 153 0.781 0.28, 1.28 0.002 0.013
 Hygiene Score, 4 0.299 0.08, 0.52 0.007 0.265
 FVC: lung function, 8 0.111 − 0.05, 0.27 0.180 0.670
 Glucose, 15 0.312 − 0.01, 0.63 0.059 0.877
Linear regression of binary outcomes. Test statistic is the change in probability that outcome has value 
0 for a 1 SD increase in log BMI age 8
 Enjoyment of School Score, 4 0.008 − 0.24, 0.25 0.949 0.309
 Self Esteem: Scholastic 
Competence, 8 0.075 − 0.10, 0.25 0.408 0.134
 Attention/activity symptoms 
score, 11 0.174 − 0.08, 0.43 0.184 0.702
 SDQ emotional symptoms 
score, 6 0.066 − 0.20, 0.33 0.621 0.046
 Self Esteem: Global Self Worth 
Score, 8 0.087 − 0.11, 0.28 0.374 0.097
 Burden of compulsions/
obsessions score, 7 0.035 − 0.06, 0.13 0.475 0.587
 Particular fears score, 7 − 0.071 − 0.28, 0.14 0.500 0.283
Table 6.  Overidentification tests of IV using CUE. Abbreviations: BMI, body mass index; CI, confidence 
interval; SD, standard deviation; IV, instrumental variable; VLDL, very low density lipoprotein; IL6, 
interleukin 6; SBP, systolic blood pressure; HDL, high density lipoprotein; SDQ, Strengths and Difficulties 
Questionnaires; LF, lung function; FVC, forced vital capacity. Categories for binary variables given in 
Supplementary Table 7. Full names of variables are given in Supplementary Table 3. Tests use all 32 SNPs 
separately in the model. aCUE: continuously updating estimator, with robust standard errors (robust 
option). bP values are not adjusted for the multiple tests performed. cLog transformed outcomes, such that 
distributions approximately normal.
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permutation testing were very different, highlighting the conservative nature of a Bonferroni correction 
when outcomes are not independent. Furthermore, we investigated an alternative Bonferroni correction 
(see Supplementary Material) that instead accounts for the number of independent variables, and this 
found 12 associations with P < 0.05 out of 128 independent outcomes (see Supplementary Material).
A Bonferroni correction should be used when concerned with the global hypothesis, such that the 
researcher wants to control the probability that at least one test is incorrectly shown to have an associa-
tion by chance, known as a false positive finding51. Bonferroni corrections use a more stringent threshold 
such that while the number of false positive findings is lower, the number of ‘true’ associations that are 
not identified (because their associated P values are above the Bonferroni corrected threshold) is higher. 
This is not helpful for hypothesis searching studies because we may then miss potentially important 
associations. Also, the cost of a false positive association is lower in hypothesis searching studies com-
pared with traditional epidemiological studies because the results will be followed up with a further 
analysis rather than claimed to be a definitive result. In a hypothesis-searching study the researcher may 
be happy to follow up n tests knowing that m% of these may be false positives, such that it may be more 
appropriate to control the false discovery rate. This false discovery rate can be adjusted by changing the 
P value threshold.
The observational associations reported by previous EWAS studies may be caused by bias or con-
founding and do not provide reliable evidence of causation. We have used Mendelian randomization 
to search for true, causal relationships. Our analyses with observational BMI across childhood found 
a much larger number of strong associations, a distinction that has been previously reported6. EWAS 
studies may be worthwhile to test observational relationships, which can then be followed up with a 
Mendelian randomization analysis. However, observational associations may be weaker than the true 
causal effect because masked confounding and measurement error can move associations towards the 
null52. The pheWAS approach has been previously used to identify associations between a set of genetic 
variants and a set of phenotypic variables18. Our approach extends the pheWAS approach in order to 
identify potentially causal associations. While pheWAS test the association of individual SNPs with 
observed phenotypes, we use an allelic score composed of variants known to be associated with a par-
ticular risk factor as an instrumental variable.
While our approach provides evidence of causality, the direction of this causal effect is less clear, as 
illustrated in Fig. 7. Instead of our hypothesized relationship, it is possible that the allele score actually 
directly affects the “outcome”, which in turn affects BMI, our “exposure” variable. For instance, as leptin 
is involved in satiation it is possible that the BMI allelic score, or a subset of variants of which it is com-
posed, affects BMI through leptin rather than vice versa. Currently, our understanding of the biological 
effects of these variants are often not sufficient to have certainty over the direction of the mechanism 
of action. Whilst it is not possible to directly test this, this can be investigated by comparing the effect 
estimates of independent instruments, as if two instruments affect the “outcome” through the “exposure” 
the estimated effect of BMI on an outcome should be consistent across different variants.
We believe hypothesis-searching with Mendelian randomization is a valuable first step towards iden-
tifying causal effects, without specifying a particular hypothesis a priori. As with GWAS, the results need 
to be followed up with further analyses on independent data. While replication is sufficient to determine 
if a GWAS association is robust, MR-pheWAS follow-up studies also need to determine if the association 
is due to a causal effect, such that causal inference can be made. Replication of an association between 
Figure 6. Distribution of the percentage of missing data, in our 8,121 sample, across the 172 outcomes. 
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an allele score and a phenotype is not enough to infer causality because this association could be due 
to an effect of the “outcome” on the “exposure” as just discussed, or because the instrumental variable 
assumptions are invalid.
Where possible it would be informative to test the association of an allelic score of an “outcome” 
(e.g. leptin) with observational BMI, to further elucidate causality through a bi-directional analysis9. To 
ensure associations found are not due to reverse causation (where the “outcome” has a causal effect on 
the “exposure”) each allelic score should be composed of variants that have a strong association only with 
the “exposure” in this bi-directional analysis53. Also, identifying homogeneity of effects between SNPs can 
provide evidence for a direction of effect. For instance, suppose the IV estimates of the effect of BMI on 
an “outcome” using the BMI SNPs individually all imply a similar effect estimate, whereas the IV esti-
mates of the effect of the “outcome” on BMI using each of “outcome” SNPs imply either heterogeneous 
or no effects, then this may suggest that BMI affects the “outcome”.
In this work we have demonstrated a hypothesis-searching approach to identify potentially causal 
effects of a risk factor, using BMI as an exemplar. Unlike traditional hypothesis driven approaches we 
test the association with a large, randomly selected set of phenotypes, rather than specifying a hypothesis 
to test a priori. We have found that observational BMI was associated with a large number of pheno-
types, illustrating the problematic nature of observational tests due to the confounding prevalent between 
observational phenotypes. These associations in observational data do not indicate causality. In contrast, 
our genetic instrument was associated with fewer phenotypes because (subject to instrumental variable 
assumptions) its constituent alleles are not associated with confounding factors, and the causal direction 
can be investigated because the genome exists prior to the observed phenotypes. We used a set of positive 
controls to validate the use of this hypothesis-searching method.
This scalable and systematic approach can be repeated with Mendelian randomization variables of 
other exposures, in order to gradually determine the causal structure of an otherwise complex network. 
As discussed, associations identified with this type of analysis would need further investigation to vali-
date the relationship through replication studies and elucidate the direction of causality.
Methods
Study population. The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospec-
tively collected pregnancy cohort that recruited pregnant women with expected delivery dates between 
April 1991 and December 1992 from Bristol, UK (see54–56 for the study details). The study was carried 
out in accordance with the ethical standards of the Helsinki Declaration, and ethical approval for data 
collection was obtained from the ALSPAC Law and Ethics Committee and local research ethics commit-
tees. Informed consent was obtained from all subjects.
A total of 9,912 ALSPAC children were genotyped using the Illumina HumanHap550 quad genome-wide 
SNP genotyping platform by the Wellcome Trust Sanger Institute, Cambridge, UK and the Laboratory 
Corporation of America, Burlington, NC, USA. Individuals were excluded from further analysis on the 
basis of having incorrect sex assignments; minimal or excessive heterozygosity (< 0.320 and > 0.345 for 
the Sanger data and < 0.310 and > 0.330 for the LabCorp data); disproportionate levels of individual 
missingness (> 3%); evidence of cryptic relatedness (> 10% IBD) and being of non-European ancestry (as 
detected by a multidimensional scaling analysis seeded with HapMap 2 individuals, EIGENSTRAT analy-
sis revealed no additional obvious population stratification and genome-wide analyses with other pheno-
types indicate a low lambda). The resulting data set consisted of 8,365 individuals and 488,311 autosomal 
SNPs. SNPs with a minor allele frequency of < 1% and call rate of < 95% were removed. Furthermore, 
only SNPs which passed an exact test of Hardy–Weinberg equilibrium (p > 5 × 10−7) were considered for 
analysis. Of these 8365 individuals, 5819 had BMI data, and 4251 had CRP and LDLc levels measured. 
Known autosomal variants were imputed with MACH 1.0.16 Markov Chain Haplotyping software, using 
CEPH individuals from phase 2 of the HapMap project (HG18) as a reference set (release 22).
After quality control assessment and imputation the data set consisted of 8,365 non-related children of 
European descent with 2,608,006 SNPs available for analysis. Of these 8,365 we removed 244 individuals 
with no data for all outcomes giving a sample size of 8,121. We restricted our analysis to individuals of 
Figure 7. Graphs illustrating two possible causal pathways to explain associations of the BMI allele 
score with the outcomes. Abbreviations: BMI, body mass index. Left graph represents the intended pathway 
we have investigated, where the BMI allele score is an IV for BMI and the variants affect the outcome solely 
through observed BMI in childhood. The right graph represents the alternative causal pathway, where the 
allelic score affects BMI indirectly through the outcome variable. It is possible that these two pathways both 
occur for a given outcome, such that the graph would become cyclical.
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white European ethnic origin to reduce the potential for population stratification, which could confound 
associations between the BMI allele score and the outcomes.
BMI allele score. We created an allele score of the BMI variants, constructed using a weighted sum of 
32 loci known to be associated with BMI (listed in Supplementary Table 1). The weights were generated 
from the effect size of BMI associated SNPs found in a large GWAS57. This GWAS did not include the 
ALSPAC study58. We constructed the score in terms of the number of BMI-increasing alleles so that a 
higher score corresponds to a higher BMI (see Supplementary Material for calculation).
Outcomes. We compiled a set of 172 continuous variables from the ALSPAC dataset, comprising a 
range of variables recorded between birth and 15 years old, including primary measures (from ques-
tionnaires or focus clinics) and also derived variables. The dataset was compiled by selecting a set of 
complete clinic assessment based data files from the ALSPAC cohort, each corresponding to a separate 
measurement event. The intention is to include a random subset of available clinic measures, rather 
than select variables where we have an a priori interest or evidence in their association with BMI. These 
were processed in turn to reduce the size of the dataset by manually removing variables where multiple 
similar variables were found. We did this by including a composite score measure where available (and 
removing its component phenotypes) or keeping only one measure from each similar group of variables. 
This delivered a diverse range of 160 randomly selected variables at a range of time points to give a rich 
outcome dataset (given in Supplementary Table 3). We also included a selected set of outcomes, as we 
need to ensure that the dataset contains variables both with and without previous evidence of an associ-
ation with BMI, such that we can validate our screening approach. We therefore included 12 outcomes, 
previously suggested to be associated (perhaps causally) with BMI: glucose31, insulin31, leptin28, age at 
menarche25, systolic blood pressure24 and C-reactive protein28,34, intelligence and attainment measures 
(Wechsler Intelligence Scale for Children (WISC), Diagnostic Analysis of Nonverbal Accuracy (DANVA), 
and literacy scores (2 phenotypes))59, lung function60 and the Home Observation for Measurement of 
the Environment (HOME) score61. Further details are given in Supplementary Table 2. Where outcomes 
were available at multiple time points we used the most complete measure. We removed values coded as 
missing, and refer to this as the original dataset.
Statistical methods. We performed all analyses using Stata v11.2 (StataCorp LP, 2009; College sta-
tion, TX, USA)62. Our main analysis, to search for associations, was a two-stage process. The first stage 
involved a large-scale analysis to screen for associations of the BMI allele score with all outcomes in our 
dataset. The second stage followed up ‘top’ associations identified in the first stage, with an IV analysis 
and sensitivity analysis assessing the degree of pleiotropy.
In the first stage we began by transforming the outcome variables in order to harmonise this dataset, 
such that a single analytical approach can be applied in the subsequent BMI score screening step. We 
used a rank-based inverse normal transformation to ensure all outcomes were normally distributed. We 
tested the associations of the BMI score with all transformed outcomes, using univariate linear regression 
analysis, with robust standard errors (the robust option). We ordered the resulting associations by P 
value to rank the associations from strongest to weakest (where a rank of 1 denotes the strongest result). 
The rank position gives an indication of the relative strength of associations of the allelic score with 
the outcome variables. We identified associations of outcomes and allele score with, as an illustration, a 
nominal P < 0.05 and took these forward for further tests in the second stage analysis.
In addition to the P values of these tests we report Bonferroni adjusted P values calculated by multi-
plying the P values by 160 to account for the number of tests performed. We exclude the validation set 
from these calculations as we have selected these phenotypes based on prior knowledge. We determine 
the proportion of our top results that are expected to be false positives, the false discovery rate (calcu-
lated as the expected number of results with P value < 0.05 by chance alone (160 × 0.05) divided by the 
number of results found with a P value < 0.05). We also report alternative permutation P values - the 
probability that an outcome at rank i, would be found at rank j where j ≤ i given there is no association 
between the BMI score and all outcomes. These are estimated using permutation testing, and we again 
exclude the validation set from this analysis. We permute the values of each outcome variable across par-
ticipants and repeat the stage 1 analysis, performing linear regression of the BMI score on each outcome 
and generating a ranking of associations. We repeat this 5,000 times to derive an empirical distribution 
of the rank position of each outcome. For each outcome at rank i we report the proportion of these tests 
where the outcome is found at rank j where j ≤ i. This gives a P value that accounts for tests with all 160 
randomly selected outcomes in the dataset. We also perform a sensitivity analysis to demonstrate the 
conservative nature of the standard Bonferroni correction (see Supplementary Material).
In the second stage of our analysis we tested each stage 2 outcome (that had an association with 
p < 0.05 in stage 1) with a formal instrumental variable analysis using two-stage least squares regression 
(the Stata ivregress command). Although the BMI allele score is a risk factor for lifelong BMI we did 
not observe lifelong BMI and so instead use this score to estimate the effect of BMI at a single time point, 
at age 8, on the outcomes. We log-transformed BMI at age 8 so that its distribution was approximately 
normal. We used the original outcome dataset (rather than the inverse normal transformed version) 
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and transformed any variables with skewed distributions (identified visually) to give distributions that 
were approximately standard normal (with mean of zero and standard deviation of one). We converted 
outcomes with distributions that were not normal and not right skewed to binary variables with approx-
imately equal numbers in each group. We used linear and logistic regression for the second stage of the 
instrumental variable analysis for normally distributed and binary outcomes respectively. Finally, we also 
tested the associations of observational (log-transformed) BMI at age 8 using the same protocol with the 
172 outcome variables, for comparison.
Testing validity of the instrumental variable assumptions. As discussed in the introduction, 
Mendelian randomization tests require the IV assumptions to be satisfied. These assumptions are; (1) 
the genetic IV is associated with the exposure (observational log BMI at age 8), (2) the genetic IV only 
affects the outcome through its effect on the exposure, and (3) the genetic IV is independent of all factors 
confounding the association between BMI and the outcomes. We used univariate linear regression (the 
Stata regress command) to test the strength of the BMI allele score as an instrument for observa-
tional BMI, where a larger F-statistic implies greater power63. We cannot directly test assumptions 2 and 
3, but we can look for evidence that the assumptions do not hold. If the 3 core instrumental variable 
assumptions hold, and either of the point identifying assumptions hold, the estimated effect of BMI on an 
outcome should be consistent across different variants. We explored this by comparing the results using 
two independent instrumental variables: (1) FTO (the SNP most strongly associated with BMI), and (2) 
the remaining 31 variants (we refer to this as the 31-allele score). FTO explains around a quarter of the 
variance of BMI explained by the other 31 combined (31 variants were associated with BMI r2 = 0.0215, 
FTO was associated with BMI r2 = 0.0055). Furthermore, we tested the strength of the associations of 
each instrument to ensure they were both strongly associated with BMI.
We performed further tests with the stage 2 outcomes (those below P < 0.05 in stage 1) to look for 
evidence that the variants were not valid instruments. When there are more instruments (genetic vari-
ants) than dependent variables (risk factors), an instrumental variable analysis is over-identified, and we 
can test for differences between estimates based on each of the variants, using over-identification tests. 
We estimated the effects of BMI using the 32 individual SNPs with the continuously updating estimator 
(CUE) via generalized method of moments (GMM), and tested for heterogeneity in these effects using 
Hansen tests64. The null hypothesis states that there is no evidence of differences in the IV effect estimates 
between different variants. Thus rejection of this test suggests there are differences between the estimates 
based on each of the variants. This may suggest that the instrumental variable assumptions do not hold, 
for example if the effects of the variants are not solely mediated through BMI.
Sensitivity analyses. We present results using the original data as our main analyses, where the sam-
ple size for each test varies depending on the outcome. This creates a potential for differences in P values 
to be caused by differences in sample size, or bias due to missing data. In order to assess the impact 
of this we repeated our analysis using an imputed dataset. We used multiple imputation with chained 
equations to create 20 imputed datasets of all 8,121 individuals and 172 variables in the original dataset 
(details of the imputation methods65 can be found in the Supplementary Material). We compared the 
ordering of the outcome variables by P value across the original and imputed versions using Spearman’s 
rank correlation.
We performed a further sensitivity analysis to test for further evidence of the associations identified 
in our IV analysis. We used 52 novel loci associated with BMI, identified in the largest GWAS to date66, 
to construct a weighted allele score, and refer to this as the 52-SNP allele score (SNPs included are given 
in Supplementary Table 8). These loci are independent to those included in our analyses. We repeat the 
IV analysis to determine if the associations using this independent IV are consistent with our original 
results.
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